AllSight
Companies · HUN · Chemicals & Allied Products · Acquisition · Aug 17, 2026

Huntsman adds merger disclosures after lawsuits; deal terms stay unchanged

Merger supplementpartly known
No merger-term change; two Huntsman complaints and one Olin complaint disclosed
Huntsman CORP (HUN) — what happened, in plain English, and what it means versus what the market expected.

The transaction was already largely known, and this filing does not change its economics. Huntsman and Olin had already signed the merger agreement, made the registration statement effective, and scheduled both shareholder meetings for August 25, 2026. The new filing is primarily a supplemental proxy disclosure intended to reduce litigation and delay risk, not a revised offer or new transaction structure. Huntsman said it “voluntarily amends and supplements the Joint Proxy Statement/Prospectus” (Supplemental disclosures) 〔0〕

The main negative is additional deal-process friction, not evidence that the merger’s underlying value has deteriorated. Two lawsuits from purported Huntsman stockholders and one from purported Olin shareholders allege disclosure omissions, with plaintiffs seeking corrective disclosures and potentially to delay the vote or merger. (Litigation disclosures) 〔1〕 (Litigation disclosures) 〔2〕

The supplemental material mostly adds valuation mechanics and confirms that Huntsman’s standalone operating outlook was stable. The updated projections cut 2026 revenue by $137 million but left 2027–2030 revenue unchanged and reduced only 2029E and 2030E adjusted EBITDA by $1 million each. (Huntsman standalone projections)

Disclosed itemHuntsmanOlin
Citi DCF implied equity value per share (Financial analyses — Citi)$15.20–$21.80$41.40–$56.30
Selected-company 2026E adjusted EBITDA (Financial analyses — Citi)$346 million—
Selected-company 2027E adjusted EBITDA (Financial analyses — Citi)$501 million—
Net debt / other items used by Lazard (Financial analyses — Lazard)$1.908 billion$2.804 billion
Fully diluted shares used by Lazard (Financial analyses — Lazard)178.068–178.241 million117.506–117.961 million

Net, this is a mildly mixed procedural update: litigation risk increases modestly, but the absence of deal-term changes, unchanged board support and largely stable projections leave the merger thesis intact. The board continues to unanimously recommend approval (Board recommendation) 〔3〕

Read the original 8-K on SEC EDGAR ↗
More from Huntsman CORP (HUN)
Aug 25, 2026Huntsman shareholders approve Olin merger, but 2027 closing still awaits regulatorsAll HUN filings, decoded →
Related companies in Chemicals & Allied Products
Latest across the market
NTSTNETSTREIT debt amendment formalizes investment-grade pricing and widens leverage cushionFLOCFlowco acquisition adds Canadian rod lift but increases debt-funded execution riskCTRECareTrust acquisition adds 45 UK care homes, but SHOP payoff is years awayIARTIntegra earnings: flooding cuts 2026 guidance as Q3 revenue misses consensusSRZNSurrozen FDA clearance unlocks $95.1M financing, but dilution followsCELCCelcuity adds director with big-pharma CFO experience as launch beginsBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact